Andrew Ko, MD
Professor
Medicine
School of Medicine

Education & Training

Show all (5) Hide

• Diversity, Equity, and Inclusion Champion Training University of California 2018
• Medical oncology (fellowship) Stanford University 06/2001
• Internal Medicine (internship and residency) Beth Israel/Harvard Medical School 06/1998
• M.D. Medicine Johns Hopkins School of Medicine 05/1995
• Sc.B. Applied Mathematics and Biology Brown University 05/1991

Websites

Show all (1) Hide

• Clinical Profile at UCSF Medical Center (ucsfhealth.org)

Grants and Projects

Show all (1) Hide

• Dual Targeting of MEK and EGFR Signaling Pathways in Advanced Pancreatic Cancer, NIH, 2011-2014

Publications (137)

Top publication keywords:
CA-19-9 AntigenAntibodies, Monoclonal, HumanizedCamptothecinAdenocarcinomaAmpulla of VaterPaclitaxelAntimetabolites, AntineoplasticCarcinoma, Pancreatic DuctalPancreatic NeoplasmsDeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsGastrointestinal NeoplasmsAlbuminsStomach NeoplasmsEsophageal Neoplasms

• Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study.
  Bioelectronic medicine 2024 Peterson D, Van Poppel M, Boling W, Santos P, Schwalb J, Eisenberg H, Mehta A, Spader H, Botros J, Vrionis FD, Ko A, Adelson PD, Lega B, Konrad P, Calle G, Vale FL, Bucholz R, Richardson RM
• A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer.
  Investigational new drugs 2024 Ko AH, Coveler AL, Schlechter BL, Bekaii-Saab T, Wolpin BM, Clark JW, Bockorny B, Bai LY, Lin YC, Chiang E, Langecker P, Lin SY
• Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer.
  Cancer research communications 2024 Soto M, Filbert EL, Yang H, Starzinski S, Starzinski A, Gin M, Chen B, Le P, Li T, Bol B, Cheung A, Zhang L, Hsu FJ, Ko A, Fong L, Keenan BP
• Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 O'Reilly EM, Ko AH, Friedberg JW
• Hyperpolarized 13 C Metabolic MRI of Patients with Pancreatic Ductal Adenocarcinoma.
  Journal of magnetic resonance imaging : JMRI 2023 Gordon JW, Chen HY, Nickles T, Lee PM, Bok R, Ohliger MA, Okamoto K, Ko AH, Larson PEZ, Wang ZJ

Show all (132 more) Hide

• Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Ko AH
• Interindividual variation in human cortical cell type abundance and expression.
  Science (New York, N.Y.) 2023 Johansen N, Somasundaram S, Travaglini KJ, Yanny AM, Shumyatcher M, Casper T, Cobbs C, Dee N, Ellenbogen R, Ferreira M, Goldy J, Guzman J, Gwinn R, Hirschstein D, Jorstad NL, Keene CD, Ko A, Levi BP, …
• Maintenance Treatment for Metastatic Pancreatic Cancer: Balancing Therapeutic Intensity with Tolerable Toxicity.
  Cancers 2023 Walker EJ, Ko AH
• Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2023 Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH,…
• Flashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Ko AH
• Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
  The oncologist 2023 Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY
• Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, …
• Precision Medicine and Immunotherapy in GI Cancers.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 O'Reilly EM, Ko AH
• Helping Patients Understand Pancreatic Cancer Using Animated Pancreas Patient Education With Visual Formats of Learning.
  Pancreas 2022 Munigala S, Gardner TB, O'Reilly EM, Fernández-Del Castillo C, Ko AH, Pleskow D, Vollmer CM, Searle NA, Bakelman D, Holt JM, Gelrud A
• Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
  Nature medicine 2022 Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C,…
• The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing.
  Pancreas 2022 Walker EJ, Blanco AM, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH
• Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis.
  American journal of clinical oncology 2022 Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH
• Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma.
  The oncologist 2021 Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M
• Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer.
  Immunotherapy 2021 Tsang ES, Walker EJ, Carnevale J, Fisher GA, Ko AH
• The jaw-dropping costs of oral cavity cancer malpractice.
  Head & neck 2021 Wong A, Zhu D, Tong JY, Ko A, Tham T, Kraus D
• Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
  The New England journal of medicine 2021 Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, …
• Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, …
• CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
  The Lancet. Oncology 2021 O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S,…
• Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
  JAMA oncology 2020 Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, …
• Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients.
  Journal of gastrointestinal oncology 2020 Hoang T, Dayyani F, Alfaro A, Huynh J, Ji J, Ko AH, Cho M, Hiyama D
• Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
  Molecular therapy : the journal of the American Society of Gene Therapy 2020 Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL
• Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, Bhinder B, Pittman ME, Plotnikova OM, …
• Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma.
  AJR. American journal of roentgenology 2020 Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM
• Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature.
  Anticancer research 2020 Burns ST, Damon L, Akagi N, Laszik Z, Ko AH
• A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners B, Ferguson AK, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT
• Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH
• Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients.
  The oncologist 2020 Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M
• Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt …
• Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer.
  The oncologist 2020 Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K
• Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH
• CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma.
  American journal of clinical oncology 2019 Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA
• Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
  Journal of gastrointestinal cancer 2019 Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K
• Adjuvant Therapy for Ampullary Cancer.
  JAMA surgery 2019 Ko AH, Nakakura EK
• Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
  Pancreas 2019 Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA
• Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
  Journal of the National Cancer Institute 2019 Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, …
• Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, …
• Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients.
  Epilepsia 2019 Wu C, Jermakowicz WJ, Chakravorti S, Cajigas I, Sharan AD, Jagid JR, Matias CM, Sperling MR, Buckley R, Ko A, Ojemann JG, Miller JW, Youngerman B, Sheth SA, McKhann GM, Laxton AW, Couture DE, Popli GS…
• Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
  Familial cancer 2019 Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH
• Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
  The American journal of surgical pathology 2019 Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE
• Pancreatic Adenocarcinoma, Version 1.2019.
  Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, …
• Understanding Pancreatic Diseases Using Animated Pancreas Patient: Informing Patients for Better Health Outcomes With Visual Formats of Learning.
  Pancreas 2018 Munigala S, Gardner TB, O'Reilly EM, Castillo CF, Ko AH, Pleskow D, Mills JB, Vollmer CM, Searle NA, Alsante M, Holt JM, Gelrud A
• Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer.
  Hepatobiliary surgery and nutrition 2018 Ko AH
• Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
  AJR. American journal of roentgenology 2018 Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA
• Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
  JAMA oncology 2018 Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G,…
• Shifting the treatment model for resectable pancreatic cancer.
  The lancet. Gastroenterology & hepatology 2018 Ko AH
• Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-…
• Clinical Management: Metastatic Disease.
  Cancer journal (Sudbury, Mass.) 2017 Ko AH
• A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
  The oncologist 2017 Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC
• Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J…
• Gastrocutaneous Fistula in a Patient with Locally Recurrent MSI-High Colorectal Cancer: Local Complications Arising from Therapeutic Response to Immune Checkpoint Blockade.
  Anticancer research 2017 Greene C, Nakakura EK, Ko AH
• A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
  The oncologist 2017 Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J
• Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
  Chinese clinical oncology 2017 Cinar P, Ko AH
• A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature.
  Journal of gastrointestinal cancer 2017 Kim SS, Kim GE, Ko AH
• Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
  Journal of gastrointestinal oncology 2016 Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP
• Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.
  American journal of clinical oncology 2016 Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T
• Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
  Pancreas 2016 Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK
• Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer.
  Journal of oncology practice 2016 Ko AH
• Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity.
  Journal of surgical oncology 2016 Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM
• Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
  Journal of surgical oncology 2016 Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH
• Safety and clinical response of intraventricular caspofungin for Scedosporium apiospermum complex central nervous system infection.
  Medical mycology case reports 2016 Williams JR, Tenforde MW, Chan JD, Ko A, Graham SM
• New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Wang VE, Grandis JR, Ko AH
• Raising the bar for the adjuvant treatment of pancreatic cancer.
  Lancet (London, England) 2016 Ko AH
• Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS
• Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
  International journal of nanomedicine 2016 Ko AH
• A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers.
  Investigational new drugs 2016 Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B
• A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
  Pancreas 2016 Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL
• Pancreatic Cancer and the Possibility of Long-term Survival: A Glimmer of Hope?
  JAMA oncology 2016 Ko AH
• A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
  Breast cancer research and treatment 2016 Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN
• CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2016 Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A
• MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer.
  Future oncology (London, England) 2015 Carnevale J, Ko AH
• A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM
• Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.
  Cancer discovery 2015 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA
• Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma.
  Hematology/oncology clinics of North America 2015 Pollom EL, Koong AC, Ko AH
• Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Ko AH
• Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study.
  Cancer 2015 Walker EJ, Ko AH, Holly EA, Bracci PM
• Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2015 Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS
• A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.
  Journal of gastrointestinal oncology 2014 Walker EJ, Simko JP, Nakakura EK, Ko AH
• Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study.
  International journal of cancer 2014 Walker EJ, Ko AH, Holly EA, Bracci PM
• Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, …
• Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
  Anticancer research 2014 Walker EJ, Simko JP, Ko AH
• 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
  Journal of gastrointestinal cancer 2014 Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP
• Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.
  Pancreas 2014 Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH
• Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.
  Cancer 2014 Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T
• Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?
  World journal of gastroenterology 2014 Walker EJ, Ko AH
• Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Cinar P, Ko AH
• Expanding options for pancreatic cancer... so where do we go from here?
  Oncology (Williston Park, N.Y.) 2014 Ko AH
• A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
  British journal of cancer 2013 Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK
• Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.
  Molecular cancer therapeutics 2013 Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM
• A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.
  British journal of cancer 2013 Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT
• Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
  Annals of oncology : official journal of the European Society for Medical Oncology 2013 Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP
• Stabilization of p21 (Cip1/WAF1) following Tip60-dependent acetylation is required for p21-mediated DNA damage response.
  Cell death and differentiation 2012 Lee MS, Seo J, Choi DY, Lee EW, Ko A, Ha NC, Yoon JB, Lee HW, Kim KP, Song J
• Two patients with primary sellar leiomyomas, a rare entity.
  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2012 Ko A, Su DK, Born D, DeSantis A, Alan Failor R, Ferreira M
• Achieving the best of both worlds.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Ko AH, Cella D
• Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
  American journal of clinical oncology 2012 Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA
• A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
  Cancer chemotherapy and pharmacology 2012 Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA
• Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
  Journal of the National Comprehensive Cancer Network : JNCCN 2012 Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, …
• Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors.
  Physical biology 2012 Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P
• Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.
  Physical biology 2012 Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, …
• Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG
• FOLFIRINOX: a small step or a great leap forward?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Ko AH
• A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
  Investigational new drugs 2011 Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK
• Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
  Nature medicine 2011 Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW
• Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis.
  Osteoarthritis and cartilage 2011 Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegård D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole …
• "And what other medications are you taking?".
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP
• Radiation therapy in operable and locally advanced pancreatic cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2010 Ko AH, Crane CH
• A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
  Cancer chemotherapy and pharmacology 2010 Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA
• A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM
• Personalized medicine for pancreatic cancer: a step in the right direction.
  Gastroenterology 2008 Ko AH, Tempero MA
• Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
  Pancreas 2008 Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA
• A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
  Investigational new drugs 2008 Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA
• Erlotinib in the treatment of advanced pancreatic cancer.
  Biologics : targets & therapy 2008 Kelley RK, Ko AH
• Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
  Cancer investigation 2008 Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA
• Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
  Journal of immunotherapy (Hagerstown, Md. : 1997) 2007 Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L
• Future strategies for targeted therapies and tailored patient management in pancreatic cancer.
  Seminars in oncology 2007 Ko AH
• A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.
  Osteoarthritis and cartilage 2007 Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS
• Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California.
  Cancer causes & control : CCC 2007 Ko AH, Wang F, Holly EA
• Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2007 Lam K, Lam FK, Lau KK, Chan YK, Kan EY, Woo J, Wong FK, Ko A
• A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
  International journal of radiation oncology, biology, physics 2007 Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA
• Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA
• Systemic therapy for pancreatic cancer.
  Seminars in radiation oncology 2005 Ko AH, Tempero MA
• Treatment of metastatic pancreatic cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2005 Ko AH, Tempero MA
• Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
  British journal of cancer 2005 Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA
• Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature.
  Digestive diseases and sciences 2003 Ko AH, Bergsland EK, Lee GA
• Clinical outcomes associated with very late relapses in diffuse large cell lymphoma.
  Leukemia & lymphoma 2002 Ko AH, Yuen AR
• Current and future strategies for combined-modality therapy in pancreatic cancer.
  Current oncology reports 2002 Ko AH, Tempero MA
• Hedgehog signaling in gastrointestinal development and disease.
  Current molecular medicine 2002 Harmon EB, Ko AH, Kim SK
• AR and ER interaction with a p21-activated kinase (PAK6).
  Molecular endocrinology (Baltimore, Md.) 2002 Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SP
• Radiation after mastectomy in high-risk patients: is it necessary?
  The American surgeon 2001 Patterson S, Ko A, O'Connell TX
• Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells.
  British journal of cancer 1998 Chen Z, Ko A, Yang J, Jordan VC
• Cavitary pulmonary lesions in patients infected with human immunodeficiency virus.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996 Gallant JE, Ko AH
• Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor.
  AIDS (London, England) 1995 Ko AH, Thomas DL, Gallant JE
• Repression, denial, backlash: sexually transmitted diseases in the People's Republic of China.
  The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha 1994 Ko AH